Shamis & Gentile, P.A. has Filed an Expanded Securities Class Action Lawsuit Against aTyr Pharma, Inc. (ATYR) and Alerts Investors of the December 8, 2025 Lead Plaintiff Deadline

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. and a senior executive for violations of federal securities laws, related to misleading statements about the company's drug trial results [1][5]. Group 1: Lawsuit Details - The lawsuit, titled King v. aTyr Pharma, Inc., is pending in the U.S. District Court for the Southern District of California [1]. - This action follows a previous class action, Munguia v. aTyr Pharma, Inc., which is the first-filed securities class action regarding the same issues [2]. - The King Action claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, covering a broader class period from November 7, 2024, to September 12, 2025 [3]. Group 2: Allegations Against aTyr Pharma - The lawsuit alleges that aTyr Pharma and its CEO made false and misleading statements about the Phase 3 EFZO-FIT trial for Efzofitimod, intended for treating pulmonary sarcoidosis [5]. - Throughout the class period, aTyr reportedly issued positive updates about the trial, claiming "remarkable steroid-sparing effects" and confidence in meeting study endpoints [6]. - On September 15, 2025, aTyr disclosed that the trial failed to meet its primary endpoint, revealing no significant change in steroid dosage, which led to a drastic stock price drop of 83.2% [6][7]. Group 3: Investor Information - Investors affected by the alleged misconduct are encouraged to seek appointment as lead plaintiff by December 8, 2025 [8]. - The law firm Shamis & Gentile, P.A. is representing the impacted investors and has a history of recovering over $1 billion for victims of securities fraud [8].